Did You Know...
...Chester Carlson was a patent agent who tired of having to make multiple copies of patent applications using the only duplication method available at the time: carbon paper. In 1959 he came up with a new copying system and took it to IBM for evaluation. The "experts" at IBM determined potential sales to be only 5,000 units because people wouldn't want to use a bulky machine when they had carbon paper. Carlson's invention was the xerography process, the company founded on the system is Xerox.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8178574 | Tosylate salt of trans-N-isobutyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-yl-methyl)-phenyl] cyclobut anecarboxamide The present invention is directed to the tosylate salt of trans-N-isobutyl-3-fluoro-3-[3-fluoro-4-(pyrrolidin-1-ylmethyl)-phenyl]-cyclobutanecarboxamide Formula (I): to solvates (e.g., hydrates) thereof, to polymorphs there... | 05/15/2012 |
| 8158673 | Histamine-3 receptor antagonists This invention is directed to a compound of formula I, as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a process of preparation of a compoun... | 04/17/2012 |
| 8138188 | Melanocortin type 4 receptor agonist piperidinoylpyrrolidines The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein the variables and substituents are as defined herein and especially to selective MCR4 agonist compounds, to their use in ... | 03/20/2012 |
| 8093400 | Compounds useful in therapy The present invention provides compounds of formula (I), or pharmaceutically acceptable derivatives thereof wherein the variables Z, Q, Ring A, V, X, Y and Y′ are as defined herein, and pharmaceutical compositions compris... | 01/10/2012 |
| 8076356 | Triazolopyridinylsulfanyl derivatives as P38 map kinase inhibitors A compound of formula (I), or a pharmaceutical acceptable salt and/or solvate (including hydrate) thereof; and the use of a compound of formula (I) in the treatment of a TNF-mediated disease, disorder, or condition, or a p3... | 12/13/2011 |
| 8071606 | Substituted pyrazinone amides useful for activation of glucokinase The present invention provides compounds of Formula (I) that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. The variab... | 12/06/2011 |
| 7977367 | Substituted imidazole propanamide glucokinase activators The present invention provides Formula (1A) compounds that act as glucokinase activators; pharmaceutical compositions thereof; and methods of treating diseases, disorders, or conditions mediated by glucokinase. X, Y, Z, R | 07/12/2011 |
| 7928099 | Pyrimido [4,5-D] azepine derivatives as 5-HTagonists The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof wherein the variables R1, R2, R3a, R3b, R3b, R3d, and... | 04/19/2011 |
| 7875615 | Substituted triazole derivatives as oxytocin antagonists The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety ... | 01/25/2011 |
| 7842713 | Fused phenyl amido heterocyclic compounds The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt or solvate thereof, wherein: Ring A is (4-12)-membered heterocyclyl; Ring B is a fused benzene ring selected from... | 11/30/2010 |
| 7829572 | Pyrido[4,3-]pyrimidin-4(3)-one derivatives as calcium receptor antagonists The present invention is directed to novel pyrido[4,3-d]pyrimidin-4(3H)-one derivatives and pharmaceutically acceptable salts thereof of structural formula I wherein the variables R1, R2, R3... | 11/09/2010 |
| 7745630 | Triazolyl piperidine arginine vasopressin receptor modulators Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: Z, O, A, V, Y and Y′ are as defined herein; are useful for treating dysmenorreah. ... | 06/29/2010 |
| 7709473 | Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors The invention relates to compounds of formula (I) prodrugs thereof, and the pharmaceutically acceptable salts of the compounds and prodrugs, wherein Ra, Rb, R1 and R2 are as defined herein; pharmaceutical compositions ther... | 05/04/2010 |
| 7671072 | Aminopyrazole derivatives as GSK-3 inhibitors The present invention provides compounds of formula (I) the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers, and prodrugs, wherein R1, R2, and R3 are as defined herein; ph... | 03/02/2010 |
| 7649003 | Substituted triazole derivatives as oxytocin antagonists The present invention relates to a class of substituted 1,2,4-triazoles of formula (1) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety ... | 01/19/2010 |
| 7649002 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined herein and especially to sele... | 01/19/2010 |
| 7618972 | Substituted triazole derivatives as oxytocin antagonists The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of the... | 11/17/2009 |
| 7557131 | Substituted triazole derivatives as oxytocin antagonists The present invention relates to substituted triazoles of formula (I), uses thereof, processes for the preparation thereof and compositions containing said compounds. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction. | 07/07/2009 |
| 7553500 | Pharmaceutical composition having uniform drug distribution and potency Pharmaceutical compositions having uniform drug distribution and potency utilizing laxofoxifene as an active ingredient and containing a silicon dioxide to reduce loss of the active ingredient during the manufacturing process and methods for manufacturing such compo... | 06/30/2009 |
| 7456170 | Triazolobenzodiazepines and their use as vasopressin antagonists Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein R represents H, C1-6 alkyl, SO2R1, SO2NR1R... | 11/25/2008 |
| 7449462 | Triazole derivatives which inhibit vasopressin antagonistic activity Compounds of formula (I), or pharmaceutically acceptable derivatives thereof, wherein: Het represents 2-pyridinyl or 2-pyrimidinyl; R1 represents H, C1-3 | 11/11/2008 |
| 7442795 | Triazole compounds useful in therapy A compound of formula (I), or a pharmaceutically acceptable derivative, wherein A, B, V, W, X, Y, and Z are as defined herein; pharmaceutical compositions thereof; and uses thereof. ... | 10/28/2008 |
| 7442702 | Prostaglandin agonists This invention relates to prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatmen... | 10/28/2008 |
| 7432299 | Method of treatment for sexual dysfunction Use of an alpha-2-delta ligand, or a pharmaceutically acceptable derivative thereof, for the manufacture of a medicament for the treatment of premature ejaculation. ... | 10/07/2008 |
| 7358374 | Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a method for effective purification of racemic lasofoxifene A method for removing impurities from racemic cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol and purified cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol useful as an estrogen agonist/antagon... | 04/15/2008 |
| 7351567 | Enzymatic resolution of selective estrogen receptor modulators The present invention relates to a process for preparing 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen-2-ol compounds useful as an estrogen agonist. ... | 04/01/2008 |
| 7291640 | Substituted triazole derivatives as oxytocin antagonists The present invention relates to a class of substituted 1,2,4-triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety ... | 11/06/2007 |
| 7255984 | Combination therapy for osteoporosis Pharmaceutical combination compositions including certain estrogen agonists/antagonists and prostaglandins or prostaglandin agonists/antagonists. The compositions are useful for the treatment of bone disorders including osteoporosis. ... | 08/14/2007 |
| RE39558 | 5-Substituted-6-cyclic-5,6,7,8-tetrahydronaphthalen 2-ol compounds which are useful for treating osteoporosis Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease. ... | 04/10/2007 |
| 7176221 | Low dose pharmaceutical composition having uniform drug distribution and potency A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manuf... | 02/13/2007 |
| RE39419 | Estrogen agonist/antagonist metabolites This invention relates to compounds that are mammalian metabolites of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol. The compounds of the invention can be used as standards for analytical assays or as intermediates fo... | 12/05/2006 |
| 7053212 | Acyclic amide and sulfonamide ligands for the estrogen receptor The present invention provides estrogen receptor (ER) ligands of structural formula (I) the pharmaceutically acceptable salts, stereoisomers, and prodrugs thereof, and the pharmaceutically acceptable salts of the... | 05/30/2006 |
| 7037530 | Method for manufacturing a low dose pharmaceutical composition having uniform drug distribution and potency A method for manufacturing a pharmaceutical composition having uniform drug distribution and potency is described which utilizes silicon dioxide to reduce the loss of active ingredient during the manufacturing process. The method is particularly useful for the manuf... | 05/02/2006 |
| 7030157 | Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins The present invention relates to pharmaceutical compositions, kits and methods comprising combinations of (−)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydro-naphthalene-2-ol or nontoxic pharmacologically acceptable acid addition salts ther... | 04/18/2006 |
| 6998423 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists Prostaglandin agonists, methods of using such prostaglandin agonists, pharmaceutical compositions containing such prostaglandin agonists and kits containing such prostaglandin agonists. The prostaglandin agonists are useful for the treatment of bone disorders includ... | 02/14/2006 |
| 6953791 | Dipeptide derivatives This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which inc... | 10/11/2005 |
| 6951850 | Dipeptide derivatives This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which inc... | 10/04/2005 |
| 6924280 | Dipeptide derivatives This invention is directed to compounds of the formula and the pharmaceutically-acceptable salts thereof, where the substituents are as defined in the Specification, which are growth hormone secretogogues and which inc... | 08/02/2005 |
| 6911456 | Use of estrogen antagonists and estrogen agonists in inhibiting pathological conditions The present invention provides novel methods of inhibiting pathological conditions related to organ systems which respond to estrogen agonists comprising administering to a mammal in need of such treatment an effective amount of a compound of formula I ... | 06/28/2005 |
| 6906202 | Purified racemic lasofoxifene and purified lasofoxifene D-tartrate and a method for effective purification of racemic lasofoxifene A method for removing impurities from racemic cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol and purified cis-6-phenyl-5-[4-(2-pyrrolidin-1-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol useful as an estrogen agonist/antagon... | 06/14/2005 |
